Abstract
To provide insight into the long-term immune response following bivalent vaccines, we sampled vaccinated patients simultaneously co-infected with Delta and BA.1. We reported that simultaneous exposure to the Delta and BA.1 S protein does not confer an additional immune advantage compared to exposure to the Omicron BA.1 S protein alone.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study has benefited from funding from the Agence Nationale de Recherches sur le Sida et les Hepatites Virales (ANRS-0154).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Written informed consent was obtained from all participants and approval was obtained from the regional review board in April 2020 (Comite de Protection des Personnes Sud Mediterranee I, Marseille, France; ID-RCB 2020-A00932-37; ID-RCB 2021-A01877-34).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵# Study Group team members are listed in the Acknowledgments
This version of the manuscript has been revised to update the introduction and discussion section in order to discuss other studies that investigated short-term immune response following bivalent vaccination with the BA-4/5 bivalent vaccine
Data Availability
All data produced in the present study are available upon reasonable request to the authors